KR101954247B1 - Complex composition comprising green tea - Google Patents
Complex composition comprising green tea Download PDFInfo
- Publication number
- KR101954247B1 KR101954247B1 KR1020110096337A KR20110096337A KR101954247B1 KR 101954247 B1 KR101954247 B1 KR 101954247B1 KR 1020110096337 A KR1020110096337 A KR 1020110096337A KR 20110096337 A KR20110096337 A KR 20110096337A KR 101954247 B1 KR101954247 B1 KR 101954247B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- green tea
- plant
- citrus
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 232
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 114
- 235000009569 green tea Nutrition 0.000 title claims abstract description 94
- 241000196324 Embryophyta Species 0.000 claims abstract description 85
- 241000207199 Citrus Species 0.000 claims abstract description 39
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 26
- 239000004575 stone Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 22
- 238000000855 fermentation Methods 0.000 claims description 18
- 230000004151 fermentation Effects 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 235000019693 cherries Nutrition 0.000 abstract description 8
- 241000167854 Bourreria succulenta Species 0.000 abstract 2
- 241000218033 Hibiscus Species 0.000 abstract 1
- 235000005206 Hibiscus Nutrition 0.000 abstract 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 19
- 210000004969 inflammatory cell Anatomy 0.000 description 17
- 235000013616 tea Nutrition 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 16
- 241001290151 Prunus avium subsp. avium Species 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 9
- 108010028144 alpha-Glucosidases Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 241000534017 Saururus chinensis Species 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 235000015205 orange juice Nutrition 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000010030 glucose lowering effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004898 kneading Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- -1 (E.g. Chemical compound 0.000 description 2
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 2
- 241000208422 Rhododendron Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 2
- 244000291414 Vaccinium oxycoccus Species 0.000 description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000004634 cranberry Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 2
- 229960004352 diosmin Drugs 0.000 description 2
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 244000097654 Cudrania tricuspidata Species 0.000 description 1
- 235000010918 Cudrania tricuspidata Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 235000011442 Prunus x yedoensis Nutrition 0.000 description 1
- 241000220307 Prunus yedoensis Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000722281 Saururus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/214—Tea
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 녹차 조성물; 및 감귤속 식물, 돌외속 식물, 꾸지뽕나무속 식물, 벚나무속 식물 및 삼백초속 식물로 이루어진 군에서 선택된 하나 이상의 식물 조성물을 포함하는 녹차 혼합 조성물을 개시한다.The present invention relates to a green tea composition; And a green tea mixed composition comprising at least one plant composition selected from the group consisting of a plant belonging to the genus Citrus, a plant belonging to the genus Citrus, a plant belonging to the genus Stone, a plant of the genus Cherry, a plant of the genus Cherry, and a plant of the genus Hibiscus.
Description
본 발명은 우수한 기호도 및 효능을 가지는 녹차 혼합 조성물에 관한 것이다.
The present invention relates to a green tea mixture composition having excellent taste and potency.
녹차는 동백나무과의 카멜리아 시넨시스(Camellia sinensis)의 싹이나 잎 속에 존재하는 산화 효소를 불활성화시키고 수분을 제거한 것이다. 녹차는 카테킨류, 아미노산, 비타민 C, 베타-카로틴, 식이 섬유 등 유익한 유효 성분들을 다량 포함하고 있다. 그리고 녹차는 항산화, 항노화, 항암, 혈중 콜레스테롤 저하, 중금속 해독, 충치 예방 및 구취 제거 등의 효과를 가진다고 알려져 있다. 하지만 이러한 뛰어난 효과를 가짐에도 불구하고, 녹차 본연의 떫고 쓴 맛 때문에 기호도가 그리 높지 않다. 이에, 기호도가 높으면서도 우수한 효과를 가지는 차 조성물에 대한 요구가 존재한다.
Green tea is the deactivation and dehydration of oxidizing enzymes present in camellia sinensis buds or leaves of Camellia sinensis . Green tea contains a lot of beneficial active ingredients such as catechins, amino acids, vitamin C, beta-carotene and dietary fiber. Green tea has been known to have effects such as antioxidation, anti-aging, anti-cancer, blood cholesterol lowering, heavy metal detoxification, tooth decay prevention and bad breath removal. However, despite these excellent effects, the bitter taste of green tea is not very good taste because of. Accordingly, there is a demand for a tea composition having a high degree of preference and an excellent effect.
본 발명에 따른 녹차 혼합 조성물은 녹차 조성물과 함께 감귤속 식물, 돌외속 식물, 꾸지뽕나무속 식물, 벚나무속 식물 및 삼백초속 식물로 이루어진 군에서 선택된 하나 이상의 식물 조성물을 포함함으로써, 우수한 혈당 감소 효과 및 염증 완화 또는 개선 효과를 가짐과 동시에, 높은 기호도를 가진다.
The green tea composition according to the present invention may contain at least one plant composition selected from the group consisting of citrus, stamens, rhubarb, cherry and Saururus, together with a green tea composition, And has a high preference degree.
본 발명의 일측면은 녹차 조성물; 및 감귤속 식물, 돌외속 식물, 꾸지뽕나무속 식물, 벚나무속 식물 및 삼백초속 식물로 이루어진 군에서 선택된 하나 이상의 식물 조성물을 포함하는 녹차 혼합 조성물을 제공한다.
An aspect of the present invention relates to a green tea composition; And at least one plant composition selected from the group consisting of a plant belonging to the genus Citrus, a plant belonging to the genus Citrus, a plant belonging to the genus Citrus, a plant belonging to the genus Citrus, a plant belonging to the genus Cherry, a plant of the genus Cherry and a plant of the genus Sambucia.
본 발명에 따른 녹차 혼합 조성물은 선명하고 진한 색을 나타내고 소비자의 기호도가 높으며, 우수한 혈당 감소 효과 및 염증 완화 또는 개선 효과를 나타낸다.
The green tea composition according to the present invention shows a clear and dark color, has a high preference of consumers, exhibits excellent blood glucose lowering effect and inflammation relieving or improving effect.
도 1은 진귤 조성물의 함유 성분을 분석한 그래프이다.
도 2는 진귤 조성물이 염증 세포 생존율 및 NO 생성에 미치는 영향을 나타낸 그래프이다(##: P<0.01).
도 3은 돌외 조성물의 함유 성분을 분석한 그래프이다.
도 4는 돌외 조성물이 염증 세포 생존율 및 NO 생성에 미치는 영향을 나타낸 그래프이다(*,#: P<0.05, **,##: P<0.01).
도 5는 녹차 조성물, 진귤 조성물 및 돌외 조성물의 녹차 혼합 조성물이 염증 세포 생존율 및 NO 생성에 미치는 영향을 나타낸 그래프이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG.
FIG. 2 is a graph showing the effect of the purified composition on inflammatory cell survival and NO production (##: P <0.01).
3 is a graph showing an analysis of the components contained in the extraneous composition.
FIG. 4 is a graph showing the effect of extracellular composition on inflammatory cell survival rate and NO production (*, #: P <0.05, **, ##: P <0.01).
FIG. 5 is a graph showing the effect of a green tea composition of a green tea composition, an orange composition, and an off-road composition on the inflammatory cell survival rate and NO production.
본 발명의 일측면은 녹차 조성물; 및 감귤속 식물, 돌외속 식물, 꾸지뽕나무속 식물, 벚나무속 식물 및 삼백초속 식물로 이루어진 군에서 선택된 하나 이상의 식물 조성물을 포함하는 녹차 혼합 조성물을 제공한다. 본 발명에 따른 녹차 혼합 조성물은 감귤속 식물, 돌외속 식물, 꾸지뽕나무속 식물, 벚나무속 식물 및 삼백초속 식물로 이루어진 군에서 선택된 하나 이상의 식물 조성물을 포함함으로써, 기호도가 높고, 녹차 고유의 색이 보다 선명하고 진하다. 또한 α-글루코시다아제(α-glucosidase)의 활성을 억제하여 우수한 혈당 감소 효과를 나타내며, 염증 세포 생존 및 NO 생성을 저해하여 뛰어난 염증 완화 또는 개선 효과를 가진다.An aspect of the present invention relates to a green tea composition; And at least one plant composition selected from the group consisting of a plant belonging to the genus Citrus, a plant belonging to the genus Citrus, a plant belonging to the genus Citrus, a plant belonging to the genus Citrus, a plant belonging to the genus Cherry, a plant of the genus Cherry and a plant of the genus Sambucia. The green tea mixed composition according to the present invention contains at least one plant composition selected from the group consisting of citrus plants, stamens, rhizomes, cherry plants and Saururus chinensis, so that the degree of preference is high, It is clear and thick. In addition, it exhibits an excellent blood glucose lowering effect by inhibiting the activity of? -Glucosidase and inhibits inflammatory cell survival and NO production, thereby exhibiting excellent inflammation relieving or improving effect.
본 발명의 일측면에서, 녹차(green tea) 조성물은 카멜리아 시넨시스(Camellia sinensis)의 잎 또는 싹을 이용하여 제조한 조성물을 의미한다. 본 발명의 다른 일측면에서, 감귤속(屬) 식물은 운향과 감귤속에 속하는 식물, 구체적으로 진귤(Citrus sunki Hort . Tanaka), 온주 밀감(C. unshiu), 당유자(C. grandis) 또는 자몽, 더 구체적으로 진귤, 온주 밀감, 당유자 또는 자몽 등 감귤속 식물의 잎 또는 줄기를 포함한다. 본 발명의 또 다른 일측면에, 돌외속(屬) 식물은 돌외속에 속하는 식물, 구체적으로 돌외(Gynostemma Pentaphyllum), 더 구체적으로 돌외속 식물의 잎 또는 줄기를 포함한다. 본 발명의 또 다른 일측면에서, 꾸지뽕나무속(屬) 식물은 뽕나무과 꾸지뽕나무속에 속하는 식물, 구체적으로 꾸지뽕나무(Cudrania tricuspidata Bureau), 더 구체적으로 꾸지뽕나무속 식물의 잎 또는 줄기를 포함한다. 본 발명의 또 다른 일측면에서, 벚나무속(屬) 식물은 장미과 벚나무속에 속하는 식물, 구체적으로 왕벚나무(Prunus yedonensis Matsumura), 더 구체적으로 벚나무속 식물의 잎 또는 줄기를 포함한다. 본 발명의 또 다른 일측면에서, 삼백초속(屬) 식물은 삼백초과 삼백초속에 속하는 식물, 구체적으로 삼백초(Saururus Chinensis Baill), 더 구체적으로 삼백초속 식물의 잎 또는 줄기를 포함한다.In one aspect of the present invention, the green tea composition refers to a composition prepared using leaves or shoots of Camellia sinensis . In another aspect of the present invention, the citrus plant is a plant belonging to the genus Citrus and citrus, specifically citrus proclamation Hort . Tanaka , C. unshiu , C. grandis , or grapefruit, more specifically, a citrus, an Indian citrus, a sugar or grapefruit. In another aspect of the present invention, a plant belonging to the subfloor, more specifically, Gynostemma Pentaphyllum ), more specifically the leaves or stems of stones. In another aspect of the present invention, the plant is a plant belonging to the genus Mulberry and the caterpillar, specifically Cudrania tricuspidata Bureau , and more specifically, the leaves or stems of a conifers. In another aspect of the present invention, the plant of the genus Cherry is a plant belonging to the genus Rosaceae, specifically Prunus yedonensis Matsumura ), more specifically, the leaves or stems of the cherry plants. In another aspect of the present invention, the Saururus chinensis is a plant belonging to Saururus chinensis and Saururus chinensis, specifically Saururus Chinensis Baill), and more specifically, the leaves or stems of the Saururian plant.
본 발명의 일측면에서, 녹차 조성물, 감귤속 식물 조성물, 돌외속 식물 조성물, 꾸지뽕나무속 식물 조성물, 벚나무속 식물 조성물 또는 삼백초속 식물 조성물은 각 식물 자체, 그 가공물 또는 그 추출물을 포함한다. 상기에서 식물 자체는 식물 그대로 뿐만 아니라 식물을 통상의 방법으로 세척한 것을 포함한다. 상기에서 추출물은 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고, 각 식물의 성분을 뽑아냄으로써 얻어진 물질을 모두 포함하는 광범위한 개념이다. 구체적으로 추출물은 가공 전 혹은 가공 후 식물에서 추출한 액, 식물을 증열한 후 냉수나 온수를 첨가하여 추출한 액, 식물을 추출한 액을 농축시킨 액 또는 식물에서 추출한 액을 분말 또는 일정한 형태로 가공한 고형 제제를 모두 포함한다.In one aspect of the present invention, the green tea composition, the citrus plant composition, the stamina plant composition, the hibiscus plant composition, the cherry plant composition or the Saururus chinensis plant composition includes each plant itself, a work product thereof or an extract thereof. In the above, the plant itself includes not only the plant but also the plant which has been washed in a usual manner. The above-mentioned extract is a broad concept including all the substances obtained by extracting the components of each plant, regardless of the extraction method, the extraction solvent, the extracted component or the form of the extract. Specifically, the extract may be a liquid extracted from plants before or after processing, a liquid extracted from plants by adding cold water or hot water, a liquid obtained by concentrating the liquid extracted from plants, or a liquid extracted from plants into solid or powder form All preparations are included.
본 발명의 일측면에서, 녹차 조성물은 덖음차(뜨겁게 달군 팬에 볶아 수분 및 청취를 제거한 차) 조성물 또는 증제차(증기로 쪄서 만든 차) 조성물을 포함한다. 본 발명의 다른 일측면에서, 녹차 조성물은 일반적인 녹차 조성물 제조 방법인 조유(찻잎의 수분을 균일하게 건조시키는 과정), 유념(찻잎의 수분 함량을 균일하게 하고 찻잎 세포 조직을 적당히 파괴하여 잘 우러나게 하는 비비기 과정), 건조, 가향 과정을 거쳐 제조된 조성물을 포함한다. In one aspect of the present invention, the green tea composition comprises a spoon (a tea roasted in hot pan and moisture removed) composition or a pot tea (steam-steamed tea) composition. In another aspect of the present invention, the green tea composition is a common green tea composition manufacturing method (a process of uniformly drying the moisture of the tea leaves), a method of making the moisture content of the tea leaves uniform and destroying the tea leaf tissue appropriately , A drying process, and a drying process.
본 발명의 일측면에서, 감귤속 식물, 돌외속 식물, 꾸지뽕나무속 식물, 벚나무속 식물 및 삼백초속 식물로 이루어진 군에서 선택된 하나 이상의 식물 조성물은 각 식물을 일반적인 차 조성물 제조 방법으로 제조한 조성물을 포함한다. 본 발명의 다른 일측면에서, 상기 식물 조성물은 각 식물을 증제(蒸製), 덖음 및 발효 중 하나 이상으로 처리한 조성물을 포함한다. 본 발명의 또 다른 일측면에서, 발효는 약발효(20 내지 30% 발효) 또는 중발효(40 내지 60% 발효)를 포함한다. 상기 발효는 식물의 잎 또는 줄기를 그에 존재하는 산화 효소로 산화시키는 것을 의미하며, 구체적으로 발효는 식물의 잎 또는 줄기를 일광 위조(햇빛에 시들게 하기)하고, 실내 정치(수분 증발을 위한 방치) 및 요청(잎 또는 줄기에 상처를 주는 과정) 과정을 반복함을 통해 이루어질 수 있다. 이 때 실내 정치 시간 및 횟수, 요청의 시간 및 횟수를 증가시킬수록 발효 정도가 높아진다. In one aspect of the present invention, at least one plant composition selected from the group consisting of citrus plants, stony plants, rhododendrons, cherry plants and Saururus chinensis comprises a composition prepared by a common tea composition manufacturing method do. In another aspect of the present invention, the plant composition comprises a composition obtained by treating each plant with at least one of steam, steam, and fermentation. In another aspect of the invention, the fermentation includes weak fermentation (20-30% fermentation) or medium fermentation (40-60% fermentation). The fermentation means that the leaves or stems of a plant are oxidized with oxidizing enzymes present therein. Specifically, the fermentation is performed by falsifying leaves or stems of a plant in daylight (soaking in sunlight) And repeating the process of requesting (hurting leaves or stalks). In this case, the more the fermentation degree is increased,
본 발명의 일측면에 따른 녹차 혼합 조성물은 감귤속 식물, 돌외속 식물, 꾸지뽕나무속 식물, 벚나무속 식물 및 삼백초속 식물로 이루어진 군에서 선택된 하나 이상의 식물 조성물을 녹차 조성물 중량을 기준으로 5 내지 70 중량%, 구체적으로는 10 내지 70중량%, 더 구체적으로는 10 내지 50중량%로 포함할 수 있다.The green tea composition according to one aspect of the present invention comprises at least one plant composition selected from the group consisting of citrus, %, Specifically 10 to 70 wt%, more specifically 10 to 50 wt%.
상기 범위로 포함할 경우 본 발명의 의도한 효과를 나타내기에 적절할 뿐만 아니라, 조성물의 안정성 및 안전성을 모두 만족할 수 있으며, 비용 대비 효과의 측면에서도 상기 범위로 포함하는 것이 적절할 수 있다. 구체적으로 식물 조성물을 상기 범위로 포함하는 경우, 녹차 혼합 조성물의 색이 선명해지고 진해짐과 동시에 녹차 혼합 조성물에 대한 기호도가 높아지는 장점이 있다.When it is included in the above range, it is not only suitable for exhibiting the intended effect of the present invention but also can satisfy both the stability and safety of the composition and may be suitably included in the above range in terms of cost effectiveness. Specifically, when the plant composition is included in the above range, there is an advantage that the color of the green tea mixture composition becomes clear and strong, and the preference for the green tea mixture composition increases.
본 발명의 일측면은 녹차 조성물, 감귤속 식물 조성물 및 돌외속 식물 조성물을 포함하는 녹차 혼합 조성물을 제공한다. 이 경우 녹차 혼합 조성물의 기호도, 수색 및 혈당 감소와 염증 개선 효과가 가장 우수하다. 상기 녹차 혼합 조성물은 감귤속 식물 조성물 및 돌외속 식물 조성물을 5:1 내지 1:5, 구체적으로 3:1 내지 1:3, 더 구체적으로 3:1 내지 1:1로 포함할 수 있다. 상기 범위로 포함할 경우 본 발명의 의도한 효과를 나타내기에 적절할 뿐만 아니라, 조성물의 안정성 및 안전성을 모두 만족할 수 있으며, 비용 대비 효과의 측면에서도 상기 범위로 포함하는 것이 적절할 수 있다.One aspect of the present invention provides a green tea mixed composition comprising a green tea composition, a citrus plant composition, and a stones plant composition. In this case, the green tea composition has the best taste, searchability, blood sugar reduction and inflammation improving effect. The green tea mixed composition may contain citrus plants composition and stone plant composition at a ratio of 5: 1 to 1: 5, specifically 3: 1 to 1: 3, more specifically 3: 1 to 1: 1. When it is included in the above range, it is not only suitable for exhibiting the intended effect of the present invention but also can satisfy both the stability and safety of the composition and may be suitably included in the above range in terms of cost effectiveness.
본 발명의 다른 일측면에 따른 녹차 혼합 조성물은 녹차 조성물 및 감귤속 식물, 돌외속 식물, 꾸지뽕나무속 식물, 벚나무속 식물 및 삼백초속 식물로 이루어진 군에서 선택된 하나 이상의 식물 조성물의 추출물일 수 있다. 상기에서 추출물은 용매 추출물을 포함하며, 용매는 유기 용매, 구체적으로 C1 내지 C5의 알코올, 더 구체적으로 메탄올, 에탄올, 이소프로필알코올, n-프로필알코올, n-부탄올 및 이소부탄올로 구성된 군으로부터 선택된 하나 이상을 포함한다. 용매 추출물은 열수 추출물보다 높은 혈당 감소 효과 및 염증 완화 또는 개선 효과를 가질 수 있다. 상기에서 추출물은 열수 추출물, 구체적으로 90 내지 100℃의 물에 30초 내지 1분 30초 동안 추출한 추출물을 포함한다. 추출 온도 및 시간이 지나치게 긴 경우 쓴 맛과 향이 강해져 오히려 기호도를 떨어뜨릴 수 있고, 추출 온도가 낮은 경우에는 맛과 향이 약해 기호도가 낮으므로, 상기 조건으로 추출하는 것이 바람직할 수 있다.The green tea composition according to another aspect of the present invention may be an extract of at least one plant composition selected from the group consisting of green tea compositions and citrus plants, stone plants, rhododendrons, cherry plants and Saururus chinensis. Wherein the extract comprises a solvent extract and wherein the solvent is selected from the group consisting of an organic solvent, in particular a C 1 to C 5 alcohol, more specifically methanol, ethanol, isopropyl alcohol, n-propyl alcohol, n-butanol and isobutanol And the like. Solvent extracts may have higher blood glucose lowering effects and inflammation relief or improvement effects than hot water extracts. The above extracts include hot-water extracts, specifically extracts extracted from 90 to 100 ° C in water for 30 seconds to 1
본 발명의 일측면에 따른 녹차 혼합 조성물은 식품 조성물일 수 있다. 상기 식품 조성물은 기호 식품 또는 건강 식품 조성물을 포함한다.The green tea mixing composition according to one aspect of the present invention may be a food composition. The food composition comprises a preference food or a health food composition.
상기 식품 조성물의 제형은 특별히 한정되지 않으나, 예를 들어, 정제, 과립제, 분말제, 드링크제와 같은 액제, 캐러멜, 겔, 바, 삼각 티백과 같은 티백, 여러 가지 형상의 덩이차 등으로 제형화될 수 있다. 특히, 삼각 티백 또는 덩이차로 제형화되는 경우 조성물의 품질 저하가 일어나지 않으며, 대량 생산이 용이하다는 점에서 바람직할 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.The formulation of the food composition is not particularly limited, but may be formulated into tablets, granules, powders, liquid preparations such as drinks, tea bags such as caramels, gels, bars, triangular tea bags, . Particularly, when it is formulated into a triangular tea bag or a tubular tea, the quality of the composition does not deteriorate and it may be preferable in terms of mass production. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.
상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1mg/kg/일 내지 5000mg/kg/일, 보다 구체적으로는 50 mg/kg/일 내지 500 mg/kg/일이 될 수 있으나, 이에 제한되지 않으며, 투여하고자 하는 대상의 연령, 건강 상태, 합병증 등의 다양한 요인에 따라 달라질 수 있다.The dosage of the active ingredient is within the level of those skilled in the art and its daily dose is, for example, from 0.1 mg / kg / day to 5000 mg / kg / day, more specifically from 50 mg / kg / day, but it is not limited thereto, and may be varied depending on various factors such as the age, health condition, and complications of the subject to be administered.
본 발명의 일측면에 따른 녹차 혼합 조성물은 약학 조성물일 수 있다. 본 발명에 따른 조성물을 의약품에 적용할 경우에는, 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제제화 할 수 있다. 본 발명의 조성물을 상법에 따라서 실시하면 용이하게 제제화할 수 있으며, 계면 활성제, 부형제, 착색제, 향신료, 안정화제, 방부제, 보존제, 수화제, 유화 촉진제, 현탁제, 삼투압 조절을 위한 염, 완충제 또는 기타 상용하는 보조제를 적당히 사용할 수 있다.The green tea mixed composition according to one aspect of the present invention may be a pharmaceutical composition. When the composition according to the present invention is applied to medicines, it may be formulated into oral or parenteral dosage forms in the form of solid, semi-solid or liquid, by adding a commonly used inorganic or organic carrier. The composition of the present invention can be easily formulated according to the conventional method, and can be easily formulated and used as a surface active agent, excipient, coloring agent, spice, stabilizer, preservative, preservative, wettable powder, emulsion accelerator, Commercially available adjuvants can be used appropriately.
상기 경구 투여를 위한 제재로는 정제(錠劑), 환제(丸劑), 과립제(顆粒劑), 연질 및 경질 캅셀제, 산제, 세립제, 분제, 액제, 유탁제(乳濁濟), 시럽제, 펠렛제 등을 들 수 있다. 이들 제형은 유효 성분 이외에 희석제(예: 락토오스, 덱스트로오스, 수크로오스, 만니톨, 솔비톨, 셀룰로오스 또는 글리신), 활택제(예: 실리카, 탈크, 스테아르산, 그의 마그네슘 또는 칼슘염 또는 폴리에틸렌 글리콜), 또는 결합제(예: 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨 카르복시메틸셀룰로오스 또는 폴리비닐피롤리딘)를 함유할 수 있다. 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제, 흡수제, 착색제, 향미제, 또는 감미제 등의 약제학적 첨가제를 함유할 수 있다. 상기 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.Examples of the agent for oral administration include tablets, pills, granules, soft and hard capsules, powders, fine granules, powders, liquids, emulsions, syrups, pellets And the like. These formulations may contain, in addition to the active ingredient, a diluent such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine, a lubricant such as silica, talc, stearic acid, magnesium or calcium salt or polyethylene glycol, (E.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidine). Optionally, disintegrating agents such as starch, agar, alginic acid or its sodium salt, absorbing agents, coloring agents, flavoring agents, or sweetening agents. The tablets may be prepared by conventional mixing, granulating or coating methods.
또한, 상기 비경구 투여를 위한 제제는 주사제, 점적제, 로션, 연고, 겔, 크림, 현탁제, 유제, 좌제(坐劑), 패취 또는 분무제일 수 있으나, 이에 제한되는 것은 아니다.In addition, the preparation for parenteral administration may be injections, drops, lotions, ointments, gels, creams, suspensions, emulsions, suppositories, patches or spraying agents, but is not limited thereto.
본 발명에 따른 상기 약학 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥, 근육, 복강, 피하 등으로 투여될 수 있다. The pharmaceutical composition according to the present invention can be administered orally, parenterally, rectally, topically, transdermally, intravenously, muscularly, intraperitoneally, subcutaneously and the like.
또한, 상기 유효 성분의 적용량은 치료 받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 적용량 결정은 당업자의 수준 내에 있다. 일반적인 투여량은 0.01mg/kg/일 내지 2000mg/kg/일이 될 수 있고 1mg/kg/일 내지 100mg/kg/일이 될 수 있으나, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.Further, the application amount of the effective ingredient will depend on the age, sex, body weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the administration route or the judgment of the prescriber. Determination of the amount of application based on these factors is within the level of those skilled in the art. Typical dosages can range from 0.01 mg / kg / day to 2000 mg / kg / day and can range from 1 mg / kg / day to 100 mg / kg / day, It is not.
본 발명의 일측면은 감귤속 식물, 돌외속 식물, 꾸지뽕나무속 식물, 벚나무속 식물 및 삼백초속 식물로 이루어진 군에서 선택된 하나 이상의 식물 조성물을 증제(蒸製), 덖음 및 발효 중 하나 이상으로 처리하여 식물 조성물을 제조하는 단계; 및 상기 단계에서 제조한 식물 조성물을 녹차 조성물과 혼합하는 단계를 포함하는 녹차 혼합 조성물 제조 방법을 제공한다. 본 발명의 다른 일측면에 따른 녹차 혼합물 조성물 제조 방법은 상기 혼합하는 단계 이후, 혼합한 조성물을 추출하는 단계를 더 포함할 수 있다. 본 발명의 또 다른 일측면에서, 추출은 열수 추출 또는 용매 추출을 포함한다. 구체적으로, 열수 추출은 90 내지 100℃의 물에 30초 내지 1분 30초 동안 추출하는 것을 포함하며, 용매 추출은 C1 내지 C5의 알코올로 추출하는 것을 포함한다.One aspect of the present invention relates to a method of treating plants, plants, and plants by treating at least one plant composition selected from the group consisting of citrus plants, stony plants, rhizome plants, cherry plants, Preparing a composition; And mixing the plant composition prepared in the above step with a green tea composition. The method for preparing a green tea mixture composition according to another aspect of the present invention may further include, after the mixing, extracting the mixed composition. In another aspect of the invention, the extraction comprises hot water extraction or solvent extraction. Specifically, the hot water extraction comprises extraction in water at 90 to 100 ° C for 30 seconds to 1
이하, 제조예 및 실험예를 들어 본 발명의 구성 및 효과를 보다 구체적으로 설명한다. 그러나 이들 제조예 및 실험예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 그에 의해 제한되는 것은 아니다.
Hereinafter, the constitution and effects of the present invention will be described in more detail with reference to Production Examples and Experimental Examples. However, these examples and experimental examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited thereto.
[제조예] [Manufacturing Example]
한국 제주도에서 자라고 있는 녹차 품종 중 하나인 금곡록의 잎을 채취한 후 당업계의 통상적인 녹차 제조 방법인 조유, 유념, 건조, 가향 과정을 거쳐 녹차 조성물을 제조하였다.Green leaves were collected from Jeju Island, South Jeju Island, and green tea composition was prepared through the process of crude oil production, care, drying, and refinement.
한국 제주도에서 돌외, 진귤, 꾸지뽕나무, 왕벚나무 및 삼백초의 잎과 줄기를 채취하여 당업계에서 통상적인 증제 또는 덖음 방법에 따라 각 식물의 조성물을 제조하였다. 또한 채취한 각 식물의 잎과 줄기를 일반적인 부분 발효차 제조 방법을 응용하여, 일광 위조, 실내 정치, 요청, 살청, 유념, 건조 과정을 통해 약발효(20 내지 30% 발효) 및 중발효(40 내지 60% 발효) 시켰다.
The leaves and stalks were collected from Jeju Island, Korea, and were used to prepare each plant composition according to a conventional method of papermaking or papermaking in the art. (20 ~ 30% fermentation) and medium fermentation (40 ~ 40% fermentation) through application of general partial fermentation tea production method, To 60% fermentation).
[실험예 1] 녹차 조성물과 식물 조성물의 혼합 조성물의 품질 평가 [Experimental Example 1] Evaluation of quality of mixed composition of green tea composition and plant composition
제조예에서 제조한 녹차 조성물과 각 식물 조성물 1종을 7:3의 비율로 혼합한 조성물을 제조하여, 녹차 조성물 대비 기호도와 수색에 대해 5점 만점을 기준으로 평가하였다. 그 결과는 아래 표와 같다.Compositions prepared by mixing the green tea composition prepared in Production Example and one kind of each plant composition in a ratio of 7: 3 were prepared, and the taste and color of the green tea composition were evaluated on the basis of five points. The results are shown in the table below.
상기 결과에서 볼 수 있듯이, 증제 방법으로 제조한 진귤 또는 돌외 조성물과 녹차 조성물을 혼합한 경우, 높은 기호도를 나타내며, 또한 녹차 고유의 색인 녹색이 보다 선명하고 진하였다. 이하, 녹차 조성물 및 진귤 또는 돌외 조성물을 포함하는 조성물을 중심으로 살펴본다.
As can be seen from the above results, when the green tea composition was mixed with the green tea composition prepared by the method of the present invention, it showed a high degree of preference and the green of the green tea was sharper and sharper. Hereinafter, a green tea composition and a composition comprising a citrus or extramargal composition will be mainly described.
[실험예 2] 식물 조성물의 혼합 비율에 따른 품질 평가[Experimental Example 2] Quality evaluation according to mixing ratio of plant composition
제조예의 녹차 조성물과 녹차 조성물 중량 대비 각각 10 내지 70 중량%의 증제 방법으로 제조한 진귤 또는 돌외 조성물을 혼합한 조성물을 제조하였다. 또한 녹차 조성물과 진귤과 돌외 조성물을 1:1로 포함하는 식물 조성물을 녹차 조성물 중량 대비 10 내지 70 중량%로 혼합한 조성물을 제조하였다. 그리고 녹차 조성물과 진귤과 돌외 조성물을 3:1로 포함하는 조성물을 녹차 조성물 중량 대비 10 내지 50 중량%로 혼합한 조성물을 제조하였다. 상기 조성물들에 대해 녹차 단독 조성물을 대조군으로 하여 기호도를 평가하였다. 그 결과는 아래 표와 같다.The green tea composition of the present invention was prepared by mixing 10 to 70% by weight of each of the green tea composition and the green tea composition. Also, a composition comprising a green tea composition, a plant composition containing 1: 1 of a citrus and a non-tea composition in an amount of 10 to 70% by weight based on the weight of the green tea composition was prepared. Then, a composition containing green tea composition, citrus peel, and off-axis composition in a ratio of 3: 1 was prepared in an amount of 10 to 50% by weight based on the weight of the green tea composition. For the above compositions, green tea alone composition was used as a control group to evaluate the degree of preference. The results are shown in the table below.
상기 결과에서 볼 수 있듯이, 진귤 조성물과 돌외 조성물이 각각 녹차 조성물과 단독으로 혼합될 때보다 양자가 함께 녹차 조성물에 혼합될 때 기호도가 높았다. 특히, 진귤과 돌외 조성물이 1:1로 혼합되는 경우에는 그 혼합 조성물이 녹차 조성물 중량 대비 20 중량%로 혼합될 때, 그리고 진귤 조성물과 돌외 조성물이 3:1로 혼합되는 경우에는 그 혼합 조성물이 녹차 조성물 중량 대비 30 중량%로 혼합될 때, 각각의 기호도가 가장 우수하였다.
As can be seen from the above results, the degree of preference was higher when the green tea composition was mixed with the green tea composition than when the green tea composition was mixed with the green tea composition alone. Particularly, in the case where the mixture of citrus peel and off-shore composition is mixed at a ratio of 1: 1, when the mixture composition is mixed at 20% by weight with respect to the weight of the green tea composition, When they were mixed in an amount of 30% by weight based on the weight of the green tea composition, the respective preferences were the best.
[실험예 3] 진귤 조성물의 생리 활성 평가[Experimental Example 3] Evaluation of physiological activity of the purified orange composition
(1) 함유 성분 평가(1) Evaluation of contained components
증제 또는 덖음 방법으로 진귤 조성물을 제조하고, 그 함유 성분을 분석하였으며, 그 결과를 도 1에 나타내었다. The orange peel composition was prepared by the method of the present invention, and the ingredients thereof were analyzed. The results are shown in FIG.
도 1에서 볼 수 있듯이, 진귤 조성물에는 노빌레틴, 탄제레틴과 같은 폴리메톡시플라본(polymethoxylflavone)이 함유되어 있으며, 주요 성분으로 디오스민(Diosmin) > 클로로겐산(Chlorogenic acid) > 탄제레틴(Tangeretin) > 노빌레틴(Nobiletin) > 루틴(Rutin)이 함유되어 있다.As shown in FIG. 1, the purified orange composition contains polymethoxylflavone such as nobiletin and tamoxifen, and diosmin> chlorogenic acid> tangeretin> It contains Nobiletin> Rutin.
(2) 고혈당 억제 효과 평가(2) Evaluation of hyperglycemia inhibitory effect
이스트 α-글루코시다아제(Yeast α-glucosidase)(0.1 U/mL, 시그마)를 소듐 포스페이트 버퍼(pH 6.8)에 준비하였다. 기질인 p-니트로페닐-α-D-글루코피라노사이드(p-nitrophenyl-α-D-glucopyranoside)(PNPG, 시그마)는 효소를 녹인 것과 같은 버퍼에 1 mM 농도로 희석하였다. 증제 또는 덖음 방법으로 제조한 진귤 조성물과 α-글루코시다아제를 섞어 37℃에서 5분간 반응시켰다. 반응 후 405 nm에서 흡광도를 측정하였고, PNPG는 1 mM의 농도로 첨가하여 시간에 따른 증가량을 측정하였다. 기질을 넣기 전 측정한 값과 넣은 후 증가하는 값을 측정하여 그 차이를 계산하고, 50% 감소시키는 시료의 농도(IC50)로 결과를 표시하였다. 대조군은 α-글루코시다아제의 우수한 저해제로 알려진 아카보스(Acarbose)(100 mg/mL, 글루코바이)를 사용하였으며 모든 실험은 3회 반복을 수행하였다. 결과는 아래 표와 같다.Yeast? -Glucosidase (0.1 U / mL, Sigma) was prepared in sodium phosphate buffer (pH 6.8). The substrate, p-nitrophenyl-α-D-glucopyranoside (PNPG, Sigma), was diluted to 1 mM in the same buffer as the enzyme was dissolved. The mixture of the orange juice composition and the α-glucosidase prepared by the method of the present invention was reacted at 37 ° C. for 5 minutes. Absorbance was measured at 405 nm after the reaction, and PNPG was added at a concentration of 1 mM to measure the increase with time. The difference was calculated by measuring the measured value before and after adding the substrate, and the result was indicated by the concentration of the sample (IC 50 ) which was decreased by 50%. The control group used Acarbose (100 mg / mL, Glucoba), which is known as an excellent inhibitor of? -Glucosidase, and all experiments were repeated three times. The results are shown in the table below.
상기 결과에서 볼 수 있듯이, 진귤의 α-글루코시다아제에 대한 뚜렷한 억제 효과는 나타나지 않았다.
As can be seen from the above results, no remarkable inhibitory effect on the α-glucosidase of the citrus fruit was observed.
(3) 염증 세포 생존율 측정 및 NO 생성 억제 효과 평가(3) Measurement of inflammatory cell survival rate and inhibition of NO production
1) 염증 세포 생존율 측정(MTT assay)1) Measurement of inflammatory cell viability (MTT assay)
시료가 LPS를 자극시켜 염증을 유발한 RAW 264.7 세포(KCLB No.40071)의 생존율에 미치는 영향을 3-(4,5-디메틸티아졸)-2,5-디페닐테트라졸리움 브로마이드(MTT)법에 의하여 측정하였다. 구체적으로, 세포 배양 후 배양액을 제거한 다음 MTT 용액 500 ㎍/ml을 첨가하고 3시간 동안 배양하였다. 배지를 제거하고, 디메틸설폭사이드(DMSO, 시그마) 300 ㎕를 가하여 MTT의 환원에 의해 생성된 포르마잔 침전물을 용해시킨 후 마이크로 플레이트 리더로 570 nm에서 흡광도를 측정하였다. 각 시료 농도에 대한 흡광도 값을 구하였으며, 대조군의 흡광도 값과 비교하여 세포 생존율(%)을 계산하였다.
The effect of the sample on the survival rate of RAW 264.7 cells (KCLB No. 40071) that stimulated LPS and induced inflammation was measured by 3- (4,5-dimethylthiazole) -2,5-diphenyltetrazolium bromide (MTT) method . Specifically, after the cell culture, the culture solution was removed, 500 μg / ml of the MTT solution was added, and the cells were cultured for 3 hours. The medium was removed and 300 μl of dimethylsulfoxide (DMSO, Sigma) was added to dissolve the formazan precipitate produced by reduction of MTT, and the absorbance at 570 nm was measured with a microplate reader. The absorbance values for each sample concentration were obtained and the cell survival rate (%) was calculated by comparing with the absorbance value of the control group.
2) NO 생성량 측정2) NO production measurement
생성된 NO의 양은 그리스(Griess) 시약을 이용하여 세포 배양액 중에 존재하는 니트라이트(nitrite)의 형태로 측정하였다. 세포 배양 상등액 100 ㎕와 그리스 시약 100 ㎕를 혼합하여 96-웰 플레이트에서 10분 동안 반응시킨 후 540 nm에서 흡광도를 측정하였다. 각 시료의 생성된 NO의 양은 소듐 니트라이드(NaNO2)를 기준으로 비교하였다.
The amount of NO produced was measured in the form of nitrite present in the cell culture medium using a Griess reagent. 100 μl of the cell culture supernatant and 100 μl of the grease reagent were mixed and reacted on a 96-well plate for 10 minutes, and the absorbance was measured at 540 nm. The amount of NO produced in each sample was compared based on sodium nitrite (NaNO 2 ).
증제 또는 덖음 방법으로 제조한 진귤 조성물에 대한 염증 세포 생존율 측정 결과와 NO 생성량 결과를 도 2에 나타내었다. 도 2에서 볼 수 있듯이, 진귤 조성물은 125 ㎍/ml 이상의 농도에서 농도 의존적으로 염증 세포 생존을 억제하는 효과를 나타내었다. 또한 진귤 조성물은 농도 의존적으로 NO 생성을 억제하였다. 이를 통해 진귤 조성물은 염증 완화 또는 개선 효과를 가짐을 알 수 있다.
The results of the measurement of inflammatory cell viability and the NO production amount of the purified orange peel composition prepared by the method of the present invention are shown in FIG. As shown in FIG. 2, the orange juice composition showed an effect of inhibiting inflammatory cell survival in a concentration-dependent manner at a concentration of 125 ㎍ / ml or more. In addition, the orange juice composition inhibited NO production in a concentration dependent manner. As a result, it can be seen that the orange juice composition has an inflammation relieving or improving effect.
[실험예 4] 돌외 조성물의 생리 활성 평가[Experimental Example 4] Evaluation of physiological activity of out-of-body composition
(1) 함유 성분 평가(1) Evaluation of contained components
증제 또는 덖음 방법으로 돌외 조성물을 제조하고, 그 함유 성분을 분석하였으며, 그 결과를 도 3에 나타내었다. 도 3에서 볼 수 있듯이, 돌외 조성물에는 루틴(Rutin), 디오스민(Diosmin)과 같은 성분이 함유되어 있었다.
The off-glaze composition was prepared by the method of evaporation or firing, and the components contained therein were analyzed. The results are shown in Fig. As can be seen from FIG. 3, the out-of-composition contained components such as Rutin and Diosmin.
(2) 고혈당 억제 효과 평가(2) Evaluation of hyperglycemia inhibitory effect
증제 또는 덖음 방법으로 제조한 돌외 조성물에 대해 실험예 3-(2)와 실질적으로 동일한 방법으로 고혈당 억제 효과를 평가하고, 그 결과를 아래 표에 나타내었다.The inhibitory effect of hyperglycemia was evaluated in substantially the same manner as in Experimental Example 3- (2), with respect to the extracellular composition prepared by the method of the present invention.
상기 결과에서 볼 수 있듯이, 돌외의 α-글루코시다아제에 대한 뚜렷한 억제 효과는 나타나지 않았다.
As can be seen from the above results, no apparent inhibitory effect on α-glucosidase was observed.
(3) 염증 세포 생존율 측정 및 NO 생성 억제 효과 평가(3) Measurement of inflammatory cell survival rate and inhibition of NO production
증제 또는 덖음 방법으로 제조한 돌외 조성물에 대해 실험예 3-(3)과 실질적으로 동일한 방법으로 염증 세포 생존율 및 NO 생성 억제 효과를 평가하고, 그 결과를 도 4에 나타내었다. 도 4에서 볼 수 있듯이, 돌외 조성물은 62.5 ㎍/ml 이상의 농도에서 농도 의존적으로 염증 세포 생존을 억제하는 효과를 나타내었다. 또한 돌외 조성물은 농도 의존적으로 NO 생성을 억제하였다. 특히 덖음 방법으로 제조한 돌외 조성물이 증제 방법으로 제조한 돌외 조성물에 비해 그 효과가 높았다. 이를 통해 돌외 조성물은 염증 완화 또는 개선 효과를 가짐을 알 수 있다.
The inflammatory cell survival rate and the inhibitory effect on NO production were evaluated by substantially the same method as in Experimental Example 3- (3), with respect to the extracellular composition prepared by the method of the present invention. As shown in Fig. 4, the out-of-body composition showed an effect of inhibiting inflammatory cell survival in a concentration-dependent manner at a concentration of 62.5 ㎍ / ml or more. In addition, the extracellular composition inhibited NO production in a concentration dependent manner. Especially, the extraneous composition prepared by the kneading method was more effective than the extruded composition prepared by the extruding method. It can be seen that the extracellular composition has an inflammation relieving or improving effect.
[실험예 5] 녹차 혼합 조성물의 생리 활성 평가[Experimental Example 5] Evaluation of physiological activity of green tea mixed composition
(1) 녹차 혼합 조성물의 제조(1) Preparation of green tea mixed composition
녹차 조성물, 진귤 조성물 및 돌외 조성물을 분쇄기로 갈아서 70% 에탄올로 10배 침적하고 실온에서 24시간 교반하여 추출하였다. 추출한 시료를 감압 여과하여 잔사를 분리한 후 여액만을 동일하게 취하여 40℃에서 회전 농축기를 이용하여 농축하고 동결 건조시켰다. 동결 건조를 마친 에탄올 추출물은 냉장 보관하였다. 수득한 녹차 조성물, 진귤 조성물 및 돌외 조성물의 용매 추출물을 실시예 1로 하였다.The green tea composition, the orange composition, and the off-axis composition were ground with a grinder, immersed 10 times in 70% ethanol, and extracted with stirring at room temperature for 24 hours. The extracted sample was filtered under reduced pressure to separate the residue. The filtrate was taken in the same way, concentrated at 40 ° C using a rotary evaporator, and lyophilized. The lyophilized ethanol extracts were refrigerated. The obtained green tea composition, the orange composition and the solvent extract of the off-road composition were as Example 1.
또한 녹차 조성물, 진귤 조성물 및 돌외 조성물을 90∼100℃ 증류수에 10배 침적하여 1분간 추출하였다. 이후 추출한 시료는 감압 여과하여 잔사를 분리하였고, 이후 과정은 용매 추출물 제조 방법과 실질적으로 동일한 방법을 사용하여 녹차 조성물, 진귤 조성물 및 돌외 조성물의 열수 추출물을 수득하고, 이를 실시예 2로 하였다. 이하, 이에 대한 생리 활성을 평가하였다.
Also, the green tea composition, the orange composition and the off-axis composition were immersed in distilled water at 90 to 100 캜 for 10 minutes and then extracted for 1 minute. The extracted samples were then filtered under reduced pressure to separate the residues. In the subsequent procedure, the green tea composition, the orange composition and the hydrothermal extract of the extraneous composition were obtained in substantially the same manner as in the solvent extract preparation method. Hereinafter, the physiological activity thereof was evaluated.
(2) 고혈당 억제 효과 평가(2) Evaluation of hyperglycemia inhibitory effect
실험예 3-(2)와 실질적으로 동일한 방법으로 녹차 조성물, 실시예 1 및 실시예 2의 조성물에 대해 고혈당 억제 효과를 평가하고, 그 결과를 아래 표에 나타내었다.The green tea composition, the compositions of Example 1 and Example 2 were evaluated for their hyperglycemia inhibitory effect in substantially the same manner as in Experimental Example 3- (2), and the results are shown in the table below.
상기 결과에서 볼 수 있듯이, 실시예 1과 2 모두 우수한 α-글루코시다아제 억제 효과를 나타내었으며, 그 중에서 용매 추출물인 실시예 1의 α-글루코시다아제 억제 효과가 더 우수하였다. 이는 진귤 조성물 및 돌외 조성물이 포함되어도 녹차 조성물의 우수한 α-글루코시다아제 억제 효과가 유지됨을 의미한다.
As can be seen from the above results, both Examples 1 and 2 showed excellent α-glucosidase inhibitory effect, and the α-glucosidase inhibitory effect of the solvent extract, Example 1, was superior. This means that the excellent α-glucosidase inhibitory effect of the green tea composition is retained even when the orange and amorphous compositions are included.
(3) 염증 세포 생존율 측정 및 NO 생성 억제 효과 평가(3) Measurement of inflammatory cell survival rate and inhibition of NO production
실험예 3-(3)과 실질적으로 동일한 방법으로 녹차 조성물, 실시예 1 및 실시예 2의 조성물에 대해 염증 세포 생존율 및 NO 생성 억제 효과를 평가하고, 그 결과를 도 5에 나타내었다.The survival rate of inflammatory cells and the inhibitory effect of NO production on the green tea composition, the compositions of Examples 1 and 2 were evaluated in substantially the same manner as in Experimental Example 3- (3), and the results are shown in FIG.
도 5에서 볼 수 있듯이, 모든 시료들은 그 농도가 증가할수록 염증 세포 생존율을 감소시키는 경향을 보였다. 그 중 실시예 1의 용매 추출물은 250 ㎕/mL 이상에서부터 급격하게 염증 세포 생존율을 감소시켰고, 500 ㎕/mL의 농도인 경우 염증 세포 생존율이 40% 이하였다. 즉, 본 발명에 따른 조성물은 우수한 염증 세포 저해 효과를 가진다. 또한, 모든 시료가 농도 의존적으로 NO 형성을 억제하였으며, 특히 실시예 1의 용매 추출물이 가장 우수한 NO 형성 억제를 나타내었다.
As can be seen from FIG. 5, all samples showed a tendency to decrease the inflammatory cell survival rate as the concentration increased. Among them, the solvent extract of Example 1 rapidly decreased the inflammatory cell survival rate from 250 ㎕ / mL or more, and the inflammatory cell survival rate was below 40% at the concentration of 500 ㎕ / mL. That is, the composition according to the present invention has an excellent inflammatory cell inhibitory effect. In addition, all the samples inhibited NO formation in a concentration-dependent manner. In particular, the solvent extract of Example 1 showed the most excellent NO formation inhibition.
상기 결과를 토대로 본 발명에 따른 조성물은 우수한 혈당 억제 효과 및 염증 완화 또는 개선 효과를 가짐을 알 수 있다.
Based on the above results, it can be seen that the composition according to the present invention has an excellent blood glucose control effect and an inflammation relieving or improving effect.
[실험예 6] 최적 음용 조건 선정[Experimental Example 6] Selection of optimum drinking condition
녹차 조성물, 진귤 조성물 및 돌외 조성물의 녹차 혼합 조성물 1.5g에 각각 70 내지 80℃, 80 내지 90℃, 90 내지 100℃의 열수를 넣고 1분, 2분, 3분 동안 추출시킨 후 기호도에 대해 15점 만점을 기준으로 10명의 평가를 받았다. 각 경우에 대한 평균 점수를 아래 표에 나타내었다.The green tea composition, the orange tea composition and the green tea mixture composition of the off-axis composition were added with hot water at 70 to 80 ° C, 80 to 90 ° C and 90 to 100 ° C for 1 minute, 2 minutes and 3 minutes, respectively, We received 10 evaluations based on the points. The average score for each case is shown in the table below.
상기 결과에서 볼 수 있듯이, 본 발명에 따른 녹차 혼합 조성물은 90 내지 100℃에서 1분 동안 추출시킨 경우 그 기호도가 가장 높았다.
As can be seen from the above results, the green tea composition according to the present invention showed the highest degree of preference when it was extracted at 90 to 100 ° C for 1 minute.
[실험예 7] 바람직한 제형 선정[Experimental Example 7] Selection of a preferable formulation
바람직한 제형을 선정하기 위해, 녹차 조성물, 진귤 조성물 및 돌외 조성물의 녹차 혼합 조성물을 6가지 제형으로 제조한 후, 그 적합성을 검토하였다. In order to select a desired formulation, the green tea composition, the orange composition and the green tea composition of the out-of-door composition were prepared in six formulations, and their suitability was examined.
입자는 균일하지 않음.Rounded
Particles are not uniform.
제형 1의 경우 녹차와 진귤 및 돌외의 색깔과 입도가 맞지 않아 적합하지 않았으며, 제형 2의 경우 분쇄된 입자에 적정 수분을 넣고 반죽하여 성형하는 것이기 때문에 자동화 공정으로 제조하기 어려울 것으로 판단되었다. 제형 3의 경우 건조시 환 표면의 균열이 생겼다. 가루 녹차 제조 방법을 사용한 제형 4의 경우 진귤 및 돌외에 의해 전체 조성물의 색도가 낮아져 적합하지 않다고 판단되었다. 제형 5는 적정 크기로 분쇄 후 삼각 티백에 넣을 경우 현대인이 시간 및 장소에 구애 받지 않고 간편하게 음용할 수 있다는 장점을 가지며 녹차 조성물과 진귤 및 돌외 조성물 간의 이질감이 없어 적합하다고 판단되었다. 제형 6은 여러 가지 성형틀을 이용하여 다양한 형상의 덩이차로 제조한 것으로, 자동화 공정으로도 제조 가능하므로 가장 바람직하다고 판단되었다.
In the case of Formulation 1, the color and particle size of green tea, orange juice, and stone were not matched, and in Formulation 2, it was judged that it would be difficult to manufacture by automation because the proper amount of water was added to the ground particles and kneaded. In
이하, 본 발명에 따른 조성물의 제형예를 보다 상세하게 설명하나, 조성물은 여러 가지 제형으로 응용 가능하고, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Hereinafter, the formulation examples of the composition according to the present invention will be described in more detail, but the composition can be applied to various formulations, and it is not intended to limit the present invention but to specifically describe it.
[제형예 1] 기호 음료의 제조 [Formulation Example 1] Preparation of a favorite drink
녹차 혼합 조성물................1000 ㎎ Green tea mixture composition: 1000 mg
구연산..........................1000 ㎎ Citric acid ......................... 1000 mg
올리고당........................100 g Oligosaccharides ........................ 100 g
타우린..........................1 g Taurine .......................... 1 g
정제수를 가하여 전체............900 ㎖ Purified water was added to complete the mixture. 900 ml
통상의 기호 음료 제조 방법에 따라 상기의 성분들을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한다. 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득한 후 밀봉 멸균한 뒤 냉장 보관하여 본 발명의 기호 음료 조성물 제조에 사용한다.The above ingredients are mixed according to the usual beverage preparation method and then stirred and heated at 85 캜 for about 1 hour. The resulting solution is filtered and sterilized in a sterilized 2-liter container, sealed, and stored in a refrigerator for use in the preparation of the preferred beverage composition of the present invention.
[제형예 2] 분말제의 제조[Formulation Example 2] Preparation of Powder Agent
녹차 혼합 조성물..................100 mg Green tea mixture composition .................. 100 mg
유당..............................100 mg Lactose .............................. 100 mg
상기의 성분들을 혼합 및 분쇄하고 백에 충진하여 분말제를 제조한다.The above components are mixed and pulverized and filled in a bag to prepare a powdered preparation.
Claims (11)
상기 돌외속 식물은 돌외속 식물의 잎 또는 줄기인 것이며,
상기 감귤속 식물 조성물 및 돌외속 식물 조성물을 3:1 내지 1:1의 중량비로 포함하고,
상기 녹차 조성물 중량을 100 중량부로 할 때 감귤속 식물 조성물 및 돌외속 식물 조성물을 10 내지 30 중량부로 포함하는, 혈당 감소용 녹차 혼합 식품 조성물.
A green tea composition, a citrus plant composition, and a stony plant composition,
The above-mentioned stony elder plants are leaves or stems of stony elder plants,
The citrus plant composition and the stone plant composition at a weight ratio of 3: 1 to 1: 1,
Wherein the green tea composition comprises 10 to 30 parts by weight of the citrus plant composition and the stone plant composition when the weight of the green tea composition is 100 parts by weight.
상기 돌외속 식물은 돌외속 식물의 잎 또는 줄기인 것이며,
상기 감귤속 식물 조성물 및 돌외속 식물 조성물을 3:1 내지 1:1의 중량비로 포함하고,
상기 녹차 조성물 중량을 100 중량부로 할 때 감귤속 식물 조성물 및 돌외속 식물 조성물을 10 내지 30 중량부로 포함하는, 염증 완화 또는 개선용 녹차 혼합 식품 조성물.
A green tea composition, a citrus plant composition, and a stony plant composition,
The above-mentioned stony elder plants are leaves or stems of stony elder plants,
The citrus plant composition and the stone plant composition at a weight ratio of 3: 1 to 1: 1,
Wherein the green tea composition comprises 10 to 30 parts by weight of the citrus plant composition and the stone plant composition when the weight of the green tea composition is 100 parts by weight.
식물 조성물은 각 식물을 증제(蒸製), 덖음 및 발효 중 하나 이상으로 처리한 조성물인, 녹차 혼합 식품 조성물.
The method according to claim 1,
A plant composition is a composition obtained by treating each plant with at least one of steam, water and fermentation.
감귤속 식물은 진귤을 포함하고, 돌외속 식물은 돌외를 포함하는, 녹차 혼합 식품 조성물.
The method according to claim 1,
Wherein the citrus plant comprises the citrus fruit, and the perennial plant comprises the perennial plant.
녹차 혼합 식품 조성물은 C1 내지 C5의 알코올 추출물인, 녹차 혼합 식품 조성물.
The method according to claim 1,
Wherein the green tea mixed food composition is an alcohol extract of C 1 to C 5 .
녹차 혼합 식품 조성물은 열수 추출물인, 녹차 혼합 식품 조성물.
The method according to claim 1,
The green tea mixed food composition is a hot water extract.
식물 조성물은 각 식물을 증제(蒸製), 덖음 및 발효 중 하나 이상으로 처리한 조성물인, 녹차 혼합 식품 조성물.
3. The method of claim 2,
A plant composition is a composition obtained by treating each plant with at least one of steam, water and fermentation.
감귤속 식물은 진귤을 포함하고, 돌외속 식물은 돌외를 포함하는, 녹차 혼합 식품 조성물.
3. The method of claim 2,
Wherein the citrus plant comprises the citrus fruit, and the perennial plant comprises the perennial plant.
녹차 혼합 식품 조성물은 C1 내지 C5의 알코올 추출물인, 녹차 혼합 식품 조성물.
3. The method of claim 2,
Wherein the green tea mixed food composition is an alcohol extract of C 1 to C 5 .
녹차 혼합 식품 조성물은 열수 추출물인, 녹차 혼합 식품 조성물.3. The method of claim 2,
The green tea mixed food composition is a hot water extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110096337A KR101954247B1 (en) | 2011-09-23 | 2011-09-23 | Complex composition comprising green tea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110096337A KR101954247B1 (en) | 2011-09-23 | 2011-09-23 | Complex composition comprising green tea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130032624A KR20130032624A (en) | 2013-04-02 |
| KR101954247B1 true KR101954247B1 (en) | 2019-03-07 |
Family
ID=48435368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110096337A KR101954247B1 (en) | 2011-09-23 | 2011-09-23 | Complex composition comprising green tea |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101954247B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230083648A (en) | 2021-12-03 | 2023-06-12 | 김선미 | Manufacturing method of blended fermented tea using concentrate |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103404638B (en) * | 2013-07-12 | 2014-11-05 | 苏州市天灵中药饮片有限公司 | Sugar-reducing tea leaves |
| CN103960395A (en) * | 2014-05-23 | 2014-08-06 | 安徽荃力电子科技有限公司 | Radix ophiopogonis healthcare tea |
| CN107647052A (en) * | 2017-10-24 | 2018-02-02 | 天峨县平昌生态农业有限公司 | A kind of blood pressure depressing health tea and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001069917A (en) * | 1999-09-02 | 2001-03-21 | Hayakawa Koso Inryo Kenkyusho:Kk | Tea including olive leaf |
| JP2010187654A (en) * | 2009-02-18 | 2010-09-02 | Akira Okubo | Tea |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090132127A (en) * | 2008-06-20 | 2009-12-30 | (주)아모레퍼시픽 | Green tea of tangerine, rape or camellia having good taste and the method for preparing thereof |
| KR20100124519A (en) | 2009-05-19 | 2010-11-29 | (주)아모레퍼시픽 | Compositions containing green tea extracts |
-
2011
- 2011-09-23 KR KR1020110096337A patent/KR101954247B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001069917A (en) * | 1999-09-02 | 2001-03-21 | Hayakawa Koso Inryo Kenkyusho:Kk | Tea including olive leaf |
| JP2010187654A (en) * | 2009-02-18 | 2010-09-02 | Akira Okubo | Tea |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230083648A (en) | 2021-12-03 | 2023-06-12 | 김선미 | Manufacturing method of blended fermented tea using concentrate |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130032624A (en) | 2013-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101483592B1 (en) | Decreasing Effect in Blood Ethanol Concentration and Improvement of Hepatic Function Including Preparation of Sprouts Hordeum Vulgare Extracts | |
| KR101959986B1 (en) | Composition of comprising vegetable worms extract cultured using mealworm or pupa and process of fabrication the extract | |
| KR101954247B1 (en) | Complex composition comprising green tea | |
| KR101871247B1 (en) | Functional grain syrup containing prunus mume extract and preparing method thereof | |
| KR20210098225A (en) | A composition for diabetes or cardiovascular disease treatment comprising a citrus fermented kombucha | |
| KR101209574B1 (en) | Pharmaceutical compositions and health functional foods compositions for the improvement of liver functions containing compound isolated from Youngia denticulata as an active ingredient | |
| KR20130032625A (en) | Complex composition comprising fermented tea | |
| KR101559483B1 (en) | Neuroprotective composition comprising extracts or fractions of seaweed as an active ingredient | |
| KR101060308B1 (en) | Diabetic treatment or prevention composition comprising natural salt and nasturtium extract | |
| KR101851167B1 (en) | Pharmaceutical composition containing extract of Spiraea prunifolia for prevention and treatment of allergic diease | |
| KR20090075481A (en) | Antioxidant composition comprising glycyrrhiza glabra extract | |
| Oboh et al. | Antioxidant properties and inhibitory effect of ethanolic extract of struchium sparganophora (ewuro odo) leaf on α-amylase and α–glucosidase activities | |
| KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
| KR100700744B1 (en) | A functional food for preventing cancer containing Canavalia gladiata extract and Houttuynia cordata extract | |
| KR101865142B1 (en) | Pharmaceutical composition containing combination extract of Spiraea prunifolia, Pyrus pyrifolia and Geum japonicum for prevention and treatment of allergic diease | |
| KR101657512B1 (en) | Urushiol free fermented Rhus verniciflua extract beverage and a method of manufacturing thereof | |
| KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
| KR101962893B1 (en) | Composition of comprising vegetable worms extract cultured using mealworm or pupa and process of fabrication the extract | |
| KR20180065419A (en) | Composition for anti-inflammation with nipa fruticans wurmb | |
| KR100782023B1 (en) | Flavonoid fractions comprising neohesperidin from citrus grandis, that having physiological activity | |
| KR20110000323A (en) | Pharmaceutical and health food composition for preventing and treating diabetes mellitus comprising fruit extracts of chaenomeles sinensis as effective component | |
| KR101817053B1 (en) | Composition for anti-oxidant or anti-cancer or anti-obesity or immune-enhancing containing Codonopsis lanceolata extract | |
| KR102721713B1 (en) | Method for preparing Citrus peel extract containing increased content of flavonoid | |
| KR20200074355A (en) | Method for Preparating functional grain syrup comprising Cynanchi wilfordii extract and functional grain syrup preparated thereby | |
| KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| E90F | Notification of reason for final refusal | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |